在配方开发中进行的药物辅助剂兼容性研究:使用本兹尼达和单糖的案例研究
Rodrigo Henrique Saatkamp1, Bruna Mattos Dos Santos1, Mariele Paludetto Sanches1
1Polymeric Materials Research Group, Chemistry Department, Federal University of Santa Catarina, Trindade, 88040-900 Florianópolis, SC, Brazil.
Journal of pharmaceutical and biomedical analysis
|August 18, 2023
概括
糖单酸盐 (GML) 增强了本兹尼达 (BNZ) 在固体配方中的溶解性. 磨或融等加工方法不会影响BNZ的结晶性,从而使得可重复的药物输送系统能够用于治疗夏加斯病.
科学领域:
- 制药科学 制药科学
- 材料科学 材料科学 材料科学
- 药物运输 药物运输 药物运输
背景情况:
- 像GML和GMS这样的单甘油 (MGs) 是口服配方的辅助剂,具有乳化特性.
- MGs可以抑制药物沉和排放,但辅助剂与药物的兼容性尚未研究.
- 唯一用于治疗夏加斯病的尼达 (BNZ) 的溶解性较差,需要改进配方.
研究的目的:
- 研究加工条件对BNZ/MG混合物的影响.
- 评估BNZ/MG混合物的物理化学特性.
- 引导开发新的固体BNZ配方.
主要方法:
- 本津醇 (BNZ) 和单糖化物 (GML,GMS) 混合物使用化,球磨和化方法制备.
- 光谱分析 (IR,1H NMR) 证实了相互作用.
- 极化光显微镜评估了固态特性.
主要成果:
- 与GMS相比,甘单酸盐 (GML) 显著改善了BNZ的溶解性.
- 在BNZ和GML之间形成的键,通过光谱学证实.
- 随着更高的GML含量,BNZ溶解度增加.
- 所有的加工方法都产生了具有可观测球体的晶体BNZ.
结论:
- 在口服配方中,GML是增强BNZ溶解性的有前途的辅助剂.
- 处理条件对BNZ固态特性的影响最小,确保配方可重复性.
- 这些发现支持开发有效的查加斯病治疗方法.
相关概念视频
Factors Influencing Drug Absorption: Pharmaceutical Parameters
154
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
154
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
229
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
229
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
333
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
333
Factors Affecting Dissolution: Particle Size and Effective Surface Area
888
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
888
Bioequivalence: Overview
1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K


